drugset / Trial / NCT05352646
NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
Phase 1
Unknown
26 enrolled
Newish Technology (Beijing) Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
NaSequentialOpen-labelTreatment
Summary
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and efficacy of autologous memory lymphocyte therapy (NewishT) in patients with hepatocellular carcinoma at high risk of recurrence after radical resection.
Timeline
- Start
- 2022-07-26
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NewishT | Cell therapy | — | Intravenous |